The iLA Membrane Ventilator is an extracorporeal ventilation system which is used primarily to remove CO2 from the patient. The system “breathes” outside of the body and carries out some gas exchange work of the native lung because the heart pumps blood through it as it does through the natural organ.
This therapy has now enabled a 36-year-old woman with severe pulmonary hypertension to survive an incredible 143 days to a lung transplant. A team of doctors from the General University Hospital in Prague used this unique form of lung support with the iLA Membrane Ventilator. The procedure involves the creation of a bypass between the main pulmonary artery, which carries blood from the heart to the lungs, and the left atrium, where oxygenated blood normally flows.
The mother of a two-year-old child was admitted without much chance of survival in December 2019. She suffered from a severe history of pulmonary hypertension, which had such a negative effect on her lung function that her blood was no longer able to flow through the lungs and be enriched with oxygen. Her only chance seemed to be a lung transplant, for which one usually has to wait between three and four months. The iLA Membrane Ventilator was successfully implanted with the support of the University Hospital Regensburg (specialists in extracorporeal heart and lung support). The therapy improved the function of the right ventricle and the entire organism. After a few days of treatment, she could move around in the hospital and improved her nutrition, which significantly enhanced her general condition for the coming transplantation.
Ten possible donors were tested for blood group and lung size, before one donor met the necessary conditions for transplantation. The operation was carried out successfully in the middle of June this year. Since then, the patient is recovering in the hospital.
Xenios AG – a company of the Fresenius Medical Care Group – is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.
Xenios’ mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients who are awake, self-determined and mobile.
Xenios AG has been part of Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group’s portfolio in the area of holistic multi-organ support of Fresenius Medical Care.
Im Zukunftspark 1
Telefon: +49 (7131) 2706-0
Telefax: +49 (7131) 2706-299
Telefon: +49 (7131) 2706-388
Fax: +49 (7131) 2706-299